3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
24
Carcinoma, Transitional Cell
6
Urinary Bladder Neoplasms
3
Carcinoma, Renal Cell
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Lung Neoplasms
2
Disease
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Brain Neoplasms
2
mCRPC (Metastatic Castration-resistant Prostate Cancer)
1
Uterine Cervical Neoplasms
1
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Rectal Neoplasms
1
Prostate Cancer Metastatic
1
Ovarian Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Interventions
Early Intervention, Educational
5
Radiotherapy
4
Psychiatric Rehabilitation
4
sargramostim
3
pembrolizumab
3
Trastuzumab
3
Methods
3
palbociclib
2
cediranib
2
Standard of Care
2
Specimen Handling
2
Mental Status and Dementia Tests
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Interleukin-12 Subunit p35
2
Interferon-alpha
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Erlotinib Hydrochloride
2
Docetaxel
2
Counseling
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
osimertinib
1
orantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Injections
×
Genitourinary
×
Clear all
NCT02584400
2019-03-08
HX4 SD
Maastricht Radiation Oncology
Phase 2
Terminated
1 enrolled